Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent quarters. The company markets Linzess in the United States in collaboration with ...

We recently published 10 Small Stocks with Mighty Gains. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the top-performing stocks on Wednesday. Ironwood Pharmaceuticals soared by 23.32 percent ...

Ironwood Pharmaceuticals IRWD announced that the FDA has accepted and granted priority review to a supplemental new drug application (sNDA), seeking expanded use of Linzess (linaclotide) for children ...

Ironwood Pharmaceuticals, Inc. IRWD along with partner Allergan AGN announced positive top-line data from the phase IIIb study on Linzess (linaclotide) for treating multiple abdominal symptoms in ...

Ironwood Pharma remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess ...

Allergan and Ironwood are going where GI commercials have not gone before: into the bathroom. A new TV ad for Linzess, begun last week, features two different people sitting on the toilet—viewers see ...

The latest round of Medicare price cuts affect 15 drugs, including Xtandi, an older prostate cancer drug from Pfizer and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...

FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...

Linzess (linaclotide), a medication for irritable bowel syndrome (IBS) with constipation or chronic idiopathic constipation is now available in American pharmacies, Ironwood Pharmaceuticals Inc. and ...